Archives
-
o2h Ventures backed In4Derm Announces a Strategic Partnership with a Nasdaq listed biotech with a >$200m Option License Agreement
11 May, 2021
-
Sunil Shah, CEO of o2h ventures, wins the Cambridge Independent Science and Technology Awards as CEO of the Year
16 April, 2021
-
University of Sussex and o2h Ventures Announce Creation and Investment in Stingray Bio, a Company for New Oncology Drugs Targeting the LMTK3 Kinase Pathway
08 April, 2021
-
The o2h human health S/EIS flagship fund – Fully Deployed
01 April, 2021
-
o2h Ventures invests into SomaServe’s successful Series A funding round
31 March, 2021
-
o2h Ventures invests in PhoreMost Series B financing
23 March, 2021
-
o2h Human Health EIS Fund leads an investment into Kuano, using quantum and AI to accelerate the development of new medicine.
25 February, 2021
-
o2h ventures backed Small Pharma receives approval for world’s first DMT for depression clinical trial
22 February, 2021
-
o2h Ventures invests into the UCL spin out company SomaServe.
22 February, 2021
invest in the growth potential of UK life science & AI